UK markets closed
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • FTSE 250

    23,608.79
    -221.39 (-0.93%)
     
  • AIM

    1,266.98
    -5.42 (-0.43%)
     
  • GBP/EUR

    1.1670
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.3676
    -0.0045 (-0.33%)
     
  • BTC-GBP

    30,796.38
    -2,002.52 (-6.11%)
     
  • CMC Crypto 200

    1,047.88
    -55.18 (-5.00%)
     
  • S&P 500

    4,451.24
    +2.26 (+0.05%)
     
  • DOW

    34,765.04
    +0.22 (+0.00%)
     
  • CRUDE OIL

    74.14
    +0.84 (+1.15%)
     
  • GOLD FUTURES

    1,750.70
    +0.90 (+0.05%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • HANG SENG

    24,192.16
    -318.82 (-1.30%)
     
  • DAX

    15,531.75
    -112.22 (-0.72%)
     
  • CAC 40

    6,638.46
    -63.52 (-0.95%)
     

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting